Why Farbe Firma is the Top Manufacturer of Ranitidine HCL Injection
- Maulik Sudani
- 3 hours ago
- 4 min read
Last Updated: May 18, 2026
TL;DR: Farbe Firma Pvt Ltd, a WHO-GMP certified pharmaceutical manufacturer in Ankleshwar, Gujarat, India, is one of the most trusted producers and CMO partners for Ranitidine HCL Injection, supplying sterile ampoule-grade product to hospitals, distributors, and government tenders across 30+ countries.
Key Takeaways
Ranitidine HCL Injection is a parenteral H2-receptor antagonist used in acute peptic ulcer, stress ulcer prophylaxis, and pre-anaesthetic gastric acid suppression.
Farbe Firma is a WHO-GMP certified, ISO 9001:2015 compliant manufacturer with ISO Class 5 (Grade A) sterile core and 100+ injectable SKUs.
CTD/ACTD-dossier-supported ranitidine ampoules and vials are exported to 30+ countries across Latin America, CIS, Africa, Middle East and South-East Asia.
Full CMO/CDMO services: formulation R&D, scale-up, ICH stability, primary/secondary packaging and regulatory support under one roof in Gujarat, India.
Introduction: Why Ranitidine HCL Injection Demands a Premium Manufacturer
Ranitidine HCL Injection is a parenteral histamine H2-receptor antagonist used to reduce gastric acid secretion in patients who cannot take oral therapy - including post-operative cases, ICU patients on stress-ulcer prophylaxis, and obstetric patients prior to general anaesthesia. Every ampoule must satisfy USP / BP / IP monograph requirements for assay, related substances, particulate matter, bacterial endotoxin (LAL) and sterility. Because the molecule has historical nitrosamine impurity concerns, every modern manufacturer must also demonstrate validated control over NDMA limits, supplier-qualified API, and tight stability protocols.
That is exactly the operating bar Farbe Firma Pvt Ltd has set since establishing its WHO-GMP certified sterile injectable facility in Ankleshwar, Gujarat, India. With ISO Class 5 (Grade A) laminar airflow filling under ISO Class 7 background, validated terminal sterilization, and end-to-end batch traceability, Farbe Firma has become a preferred Ranitidine HCL Injection manufacturer for hospital procurement chains, importers and government tender buyers worldwide.
What Sets a World-Class Ranitidine Manufacturer Apart
Manufacturing sterile parenteral ranitidine is technically more demanding than producing oral ranitidine tablets. The product must pass clarity, sub-visible particulate (USP <788>), bacterial endotoxin (LAL), sterility and assay tests at every batch - and every step is reviewed by the in-house Quality Assurance team before any ampoule is released. Farbe Firma's ranitidine line uses Type I borosilicate glass ampoules and vials, validated terminal sterilization cycles, and 100% visual plus automated particulate inspection.
Equally important is regulatory readiness. Ranitidine is registered as a prescription parenteral in most jurisdictions, so buyers need a manufacturer who can supply CTD or ACTD dossiers, country-specific labeling artwork, certificates of analysis (CoA), certificates of origin and free-sale certificates without delay. Farbe Firma's regulatory affairs team has supported dossier submissions and product registrations across Latin America, Africa, the GCC, CIS and ASEAN - making us a CDMO partner rather than just a vendor.
Quality Systems Behind Every Ranitidine Ampoule
Each batch of Ranitidine HCL Injection at Farbe Firma passes through tightly controlled in-process checks: pre-sterilization bioburden, fill-volume verification, post-fill leak testing, terminal sterilization cycle validation, NDMA impurity monitoring and finished-product assay against the relevant pharmacopoeia. Stability programs run at 25C/60% RH and 40C/75% RH per ICH Q1A(R2) guidelines, supporting 24- to 36-month shelf life claims.
Documentation includes batch manufacturing records (BMR), batch packaging records (BPR), validated cleaning records, environmental monitoring data and qualified-person review - all retained and reproducible for any future audit. The same SOPs apply whether the product is destined for a domestic hospital chain or a Ministry of Health tender in West Africa.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Ranitidine HCL Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified, ISO 9001:2015 compliant pharmaceutical manufacturer headquartered in Gujarat, India. The facility is designed around dedicated injectable suites with ISO Class 5 sterile core, water-for-injection (WFI) loop validated for endotoxin and conductivity, and validated terminal sterilization for ampoules and small-volume vials. The plant supplies 100+ injectable SKUs and exports to 30+ countries across five continents.
Beyond manufacturing, Farbe Firma operates as a true CDMO. We support contract development from formulation through validation, scale-up, dossier preparation, product registration assistance and life-cycle management. For ranitidine, our regulatory team works in close coordination with the buyer's national health authority to ensure import licensing, pharmacopoeial compliance, NDMA risk-management documentation and post-market pharmacovigilance requirements are satisfied.
Pricing, lead-time and minimum-order-quantity (MOQ) flexibility are why distributors, hospital groups and government tender buyers choose Farbe Firma year after year. Whether you need a one-time tender shipment or a multi-year supply agreement under a master CMO contract, the answer is the same: WHO-GMP quality, on-time delivery, complete documentation, and a partner who treats your market like our own.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma's Ranitidine HCL Injection WHO-GMP certified?
Yes. The entire injectable facility where Ranitidine HCL Injection is manufactured operates under valid WHO-GMP certification, ISO 9001:2015 quality management, and ISO Class 5 sterile core conditions. Certificates and inspection reports are available on request.
What ampoule sizes and strengths are available?
Standard configurations include 50 mg/2 mL clear Type I glass ampoules. Custom strengths, fill volumes and country-specific carton/leaflet artwork are available subject to MOQ and regulatory feasibility.
How does Farbe Firma manage NDMA impurity risk in Ranitidine?
We use NDMA-qualified API from a short list of approved sources, run validated UPLC test methods at batch release, and apply ICH-aligned long-term stability protocols. Our QA team reviews NDMA results before every batch release and shares the data in the dossier.
Do you provide CTD/ACTD dossiers for Ranitidine HCL Injection?
Yes. Our regulatory affairs team prepares complete CTD or ACTD dossiers - including module 3 quality data, NDMA control strategy, stability summaries and CMC sections - to support product registration in Latin America, CIS, MENA, ASEAN and African markets.
What is the minimum order quantity and lead time for Ranitidine HCL Injection?
Typical MOQ starts from 25,000 ampoules per SKU; lead time ranges 6-10 weeks from purchase order subject to API availability and country-specific artwork approval. Faster lead times are possible for repeat orders under a CMO framework agreement.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments